natgillin/translations-raw huggingface dataset:
If you use more Neupopeg than you should contact your doctor, nurse or pharmacist. 
Če uporabite več Neupopega, kot bi smeli, se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom.
There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at low subcutaneous doses. 
Pri potomcih brejih podgan, ki so jim subkutano dali pegfilgrastim, niso opazili neželenih učinkov, pri kuncih pa so pokazali, da pegfilgrastim v majhnih subkutanih odmerkih povzroča toksičnost za zarodek in plod (izgubo zarodka).
Neupopeg contains sorbitol. 
Neupopeg vsebuje sorbitol.
It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse, or pharmacist. 
Pomembno je, da si injekcije ne poskušate dati sami, če vas nista zdravnik ali medicinska sestra tega posebej naučila.
• if you experience a cough, fever and difficulty breathing; 
• če začnete kašljati, se vam zviša telesna temperatura in začnete s težavo dihati;
How do you, or the person injecting you, use Neupopeg pre-filled pen (SureClick)? 
Kako naj vi sami ali oseba, ki vam injicira zdravilo, uporabite napolnjeni injekcijski peresnik Neupopeg (SureClick)?
Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell disease. 
Pri bolnikih s srpasto anemijo je bila uporaba pegfilgrastima povezana s srpastocelično krizo.
The most frequently reported and very common study-drug related undesirable effect was bone pain Bone pain was generally of mild-to-moderate severity, transient and could be controlled in most patients with standard analgesics. 
Bolečina v kosteh je bila na splošno blage do zmerne stopnje, prehodna in jo je bilo pri večini bolnikov mogoče obvladati s standardnimi analgetiki.
Do not remove the grey needle shield from the pre-filled pen until you are ready to inject. 
Ne snemite sivega pokrovčka z injekcijskega peresnika, dokler niste pripravljeni na injiciranje.
For further instructions on how to inject yourself with Neupopeg, please read the section at the end of this leaflet. 
Nadaljnja navodila za samoinjiciranje Neupopega si preberite v poglavju na koncu tega navodila za uporabo.
Over the entire study, the rate of febrile neutropenia was 13% of pegfilgrastim-treated patients compared with 20% of filgrastim-treated patients (difference 7%, 95% CI of -19%, 5%). 
V celotni študiji je bila pogostost febrilne nevtropenije pri bolnikih, zdravljenih s pegfilgrastimom, 13 %, pri bolnikih, zdravljenih s filgrastimom, pa 20 % (razlika 7 %, 95-% interval zaupanja -19 %, 5 %).
The active substance is pegfilgrastim. 
Zdravilna učinkovina je pegfilgrastim.
Rare (≥ 1/10,000 to < 1/1,000) cases of thrombocytopenia and leukocytosis have been reported. 
Poročali so o redkih (≥ 1/10.000 do < 1/1.000) primerih trombocitopenije in levkocitoze.
You may take Neupopeg out of the refrigerator and keep it at room temperature (not above 30°C) for no longer than 3 days. 
Neupopeg smete vzeti iz hladilnika in ga hraniti pri sobni temperaturi (pod 30 ºC) največ 3 dni dolgo.
The incidence of febrile neutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1% versus 17%, p<0.001). 
Incidenca febrilne nevtropenije je bila nižja pri bolnicah, ki so dobivale pegfilgrastim, kot pri tistih, ki so dobivale placebo (1 % v primerjavi s 17 %, p < 0,001).
• if you get left upper abdominal pain or pain at the tip of your shoulder. 
• če začutite bolečino levo zgoraj v trebuhu ali v predelu leve lopatice;
Neupopeg should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens. 
Neupopega ne smete uporabljati za zvečevanje odmerka citotoksične kemoterapije preko uveljavljenih shem odmerjanja.
How do I prepare my Neupopeg injection? 
Kako si pripravim injekcijo Neupopega?
Accidental exposure to freezing temperatures for a single period of less than 24 hours does not adversely affect the stability of Neupopeg. 
Če je Neupopeg pomotoma izpostavljena temperaturam pod lediščem za enkratno obdobje, ki ne preseže 24 ur, to ne škoduje njegovi stabilnosti.
Excipients known to have a recognised action: sorbitol E420, sodium acetate (see section 4.4). 
Pomožne snovi z znanim delovanjem: sorbitol E420, natrijev acetat (glejte poglavje 4.4).
Only use a single Neupopeg pre-filled pen for each injection. 
Vsak napolnjeni injekcijski peresnik Neupopega uporabite samo za eno injiciranje.
• a pre-filled syringe of Neupopeg; and 
• napolnjeni injekcijski peresnik Neupopega;
Check the expiry date on the pre-filled pen label (EXP:). 
Preverite datum izteka roka uporabnosti zdravila na nalepki napolnjenega injekcijskega peresnika (Uporabno do:).
• The used pre-filled pen should be disposed of in accordance with local requirements. 
• Uporabljene injekcijske peresnike zavrzite v skladu z lokalnimi zahtevami.
Allergic-type reactions, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea, hypotension, injection site reactions, erythaema and flushing, occurring on initial or subsequent treatment have been reported with Neupopeg. 
Med začetnim ali nadaljnjim zdravljenjem z Neupopegom so bile opisane alergijske reakcije, vključno z anafilaksijo, izpuščajem na koži, urtikarijo, angioedemom, dispnejo, hipotenzijo, reakcijami na mestu injiciranja, eritemom in zardevanjem.
*Produced in Escherichia coli cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG). 
* Pegfilgrastim izdelujejo s tehnologijo rekombinantne DNA v celicah Escherichia coli kateri sledi konjugacija z polietilenglikolom (PEG).
The effect of Neupopeg on the ability to drive or use machines is not known. 
Učinek Neupopega na sposobnost upravljanja vozil in strojev ni znan.
• plan to become pregnant. 
• načrtujete zanositev.
Once a syringe has been removed from the refrigerator and has reached room temperature (not above 30°C) it must either be used within 3 days or disposed of. 
Ko injekcijsko brizgo vzamete iz hladilnika in le-ta doseže sobno temperaturo (pod 30 ºC), jo morate bodisi v 3 dneh porabiti ali pa zavreči.
0.6 ml of solution for injection in a pre-filled syringe (Type I glass), with a rubber stopper, and with a stainless steel needle. 
0,6 ml raztopine za injiciranje v napolnjeni injekcijski brizgi (iz stekla tipa I) z batnim zamaškom in nerjavno iglo.
Increased spleen size and very rare cases (likely to occur in fewer than 1 in 10,000 patients)) of spleen rupture have been reported after the use of Neupopeg. 
Poročali so o povečani vranici in zelo redko (verjetno je, da se bodo pojavile pri manj kot 1 od 10.000 bolnikov) o primerih rupture vranice po uporabi Neupopega.
In one study (n=157), which used a 6mg fixed dose of pegfilgrastim the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.8 days compared with 1.6 days in the filgrastim group (difference 0.23 days, 95% CI -0.15, 0.63). 
V eni študiji (n=157), v kateri so uporabili stalni odmerek 6 mg pegfilgrastima, je bilo srednje trajanje nevtropenije 4. stopnje v skupini s pegfilgrastimom 1,8 dni, v skupini s filgrastimom pa 1,6 dni (razlika 0,23 dneva, 95-odstotni interval zaupanja -0,15, 0,63).
What Neupopeg is and what it is used for Before you use Neupopeg How to use Neupopeg Possible side effects 
Kaj je Neupopeg in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili Neupopeg
The pre-filled pen has a safety cover that will protect you from needle sticks or loss of drug by accidental bumping or touching. 
Napolnjeni injekcijski peresnik ima pokrovček, ki preprečuje, da bi se po nesreči zbodli z iglo ali da bi zaradi naključnega sunka ali dotika prišlo do izgube zdravila.
Very rare (< 1/10,000) elevations in liver function tests (LFTs) for ALT (alanine aminotransferase) or AST (aspartate aminotransferase), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy. 
Zelo redko (< 1/10.000) so se bolnikom, ki so po citotoksični kemoterapiji dobili pegfilgrastim, pojavila zvišanja jetrnih funkcijskih testov ALT (alanin-aminotransferaze) ali AST (aspartataminotransferaze).
It is a clear, colourless liquid. 
Neupopeg je bistra, brezbarvna tekočina.
Do not use Neupopeg after the expiry date which is stated on the box and on the syringe label (EXP). 
Neupopega ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlici in na nalepki injekcijske brizge poleg oznake »Uporabno do«.
The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex) (see section 4.4). 
Pokrovček igle na napolnjeni injekcijski brizgi vsebuje suh naravni kavčuk (derivat lateksa) (glejte poglavje 4.4).
Press the pre-filled pen firmly enough against the skin so that the safety cover is fully retracted (see picture 6). 
Pomembno pri koraku A postopka injiciranja Napolnjeni injekcijski peresnik pritisnite na kožo dovolj močno, da se varnostni pokrovček popolnoma umakne (glejte sliko 6).
Neupopeg is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy. 
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba Neulaste ni priporočljiva pri otrocih, mlajših od 18 let.
In a second study (n=310), which used a weight-adjusted dose (100 microgramsg/kg), the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.7 days, compared with 1.8 days in the filgrastim group (difference 0.03 days, 95% CI -0.36, 0.30). 
V drugi študiji (n=310), v kateri so uporabljali za telesno maso popravljen odmerek (100 mikrogramov/kg), je bilo srednje trajanje nevtropenije 4. stopnje v skupini s pegfilgrastimom 1,7 dni, v skupini s filgrastimom pa 1,8 dni (razlika 0,03 dneva, 95-odstotni interval zaupanja -0,36, 0,30).
Very rarely (likely to occur in fewer than 1 in 10,000 patients) cutaneous vasculitis (inflammation of the blood vessels in the skin) has occurred in patients receiving Neupopeg. 
Zelo redko (verjetno je, da se bo pojavil pri manj kot 1 od 10.000 bolnikov) je pri bolnikih, ki so prejemali Neupopeg, prišlo do kožnega vaskulitisa (vnetja krvnih žil v koži).
Do not use Neupopeg after the expiry date which is stated on the box and on the pen label (EXP). 
Neupopega ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlici in na nalepki injekcijskega peresnika poleg oznake »Uporabno do«.
The usual dose is one 6 mg subcutaneous injection (injection under your skin) using a pre-filled syringe and it should be given approximately 24 hours after your last dose of chemotherapy at the end of each chemotherapy cycle. 
Običajni odmerek je ena 6-miligramska subkutana injekcija (podkožna injekcija) z uporabo napolnjene injekcijske brizge, ki jo morate prejeti približno 24 ur po zadnjem odmerku kemoterapije na koncu vsakega cikla kemoterapije.
If you notice a spot of blood at the injection site dab away with a cotton ball or tissues. 
Če se na mestu injiciranja pojavi kapljica krvi, jo popivnajte s kosmom vate ali zložencem gaze.
The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p<0.001; and 2% versus 10%, p<0.001) 
Med prejemnicami pegfilgrastima je bila tudi manjša incidenca hospitalizacij in intravensko uporabljene antiinfektivne terapije, povezanih s klinično diagnozo febrilne nevtropenije, kot med prejemnicami placeba (1 % v primerjavi s 14 %, p < 0,001, ter 2 % v primerjavi z 10 %, p <
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2). 
• POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Common (≥ 1/100 to <1/10) but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture, including some fatal cases, have been reported following administration of pegfilgrastim (see section 4.4). 
Po uporabi pegfilgrastima so poročali o pogostih (≥ 1/100 do < 1/10), a v splošnem asimptomatskih primerih splenomegalije, zelo redko pa o primerih rupture vranice, vključno z nekaj smrtnimi primeri (glejte poglavje 4.4).
You must stop breast feeding if you use Neupopeg. 
Če uporabljate Neupopeg, morate prenehati dojiti.
Pegfilgrastim should be permanently discontinued in patients who experience a serious allergic reaction. 
Bolnikom, pri katerih je prišlo do resne alergijske reakcije, je treba pegfilgrastim dokončno ukiniti.
What Neupopeg contains 
Kaj vsebuje Neupopeg
See leaflet for further information. 
Za podrobnosti glejte navodila za uporabo.
A. Centre the pre-filled pen in the area of the pinched skin at a right angle (90 degrees) and push firmly against the skin. 
A. Napolnjeni injekcijski peresnik prislonite pravokotno na sredino kožne gube (pod kotom 90 stopinj), nato ga čvrsto pritisnite na kožo in zadržite.
Pack size of one, in either blistered or non-blistered packaging. 
Pakiranje po 1 s pretisnimi omoti ali brez pretisnih omotov.
Remove from the refrigerator. 
Vzemite napolnjeno injekcijsko brizgo Neupopega iz hladilnika.
Your platelet count may become low which might result in bruising. 
Morda se bo znižala vaša koncentracija krvnih ploščic, kar lahko povzroči nastajanje modric.
Allergic-type reactions to Neupopeg, including redness and flushing, skin rash, raised areas of the skin that itch and anaphylaxis (weakness, drop in blood pressure, difficulty breathing, swelling of the face), have rarely (likely to occur in fewer than 1 in 1000 patients) been reported. 
Redko so poročali o alergijskih reakcijah zaradi Neupopega (verjetno je, da se bodo pojavile pri manj kot 1 od 1000 bolnikov), vključno s pordelostjo in zardevanjem, izpuščajem na koži, dvignjenimi in srbečimi predeli kože in anafilaksijo (slabost, padec krvnega pritiska, težave z dihanjem, otekanje obraza).
The other ingredients are sodium acetate, sorbitol (E420), polysorbate 20 and water for injections. 
Pomožne snovi so natrijev acetat, sorbitol (E420), polisorbat 20 in voda za injekcije.
Press the pre-filled pen firmly enough against the skin so that the safety cover is fully retracted (see picture 3). 
Pomembne informacije za korak A v postopku injiciranja Napolnjeni injekcijski peresnik pritisnite na kožo dovolj močno, da se varnostni pokrovček popolnoma umakne (glejte sliko 3).
Excipients known to have a recognised action: sorbitol (E420), sodium acetate. 
Pomožne snovi z znanim delovanjem: sorbitol (E420), natrijev acetat.
A small (n=83), Phase II, randomised, double-blind study in patients receiving chemotherapy for de novo acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim, administered during induction chemotherapy. 
faze pri bolnikih, ki so dobivali kemoterapijo zaradi de novo akutne mieloične levkemije, je primerjala pegfilgrastim (enkraten odmerek 6 mg) s filgrastimom ob aplikaciji med indukcijsko kemoterapijo.
Common (≥ 1/100 to < 1/10) but generally asymptomatic cases of splenomegaly and very rare (< 1/10,000) cases of splenic rupture, including some fatal cases, have been reported following administration of pegfilgrastim. 
Po uporabi pegfilgrastima so poročali o pogostih (≥ 1/100 do < 1/10), a v splošnem asimptomatskih primerih splenomegalije, zelo redko (< 1/10.000) pa o primerih rupture vranice, vključno z nekaterimi smrtnimi primeri.
Before you inject Neupopeg you must do the following: Hold the syringe barrel and gently take the cover from the needle without twisting. 
Primite telo injekcijske brizge ter nežno in brez sukanja potegnite pokrovček z igle.
A. Place the pre-filled pen on the injection site at a right angle (90 degrees) and push firmly against the skin. 
A. Napolnjeni injekcijski peresnik prislonite pravokotno na injekcijsko mesto (pod kotom 90 stopinj), nato ga čvrsto pritisnite na kožo in zadržite (glejte sliko).
Neupopeg is a solution for injection in a pre-filled pen (6 mg/0.6 ml). 
Neupopeg je raztopina za injiciranje v napolnjenem injekcijskem peresniku (6 mg/0,6 ml).
NAME OF THE MEDICINAL PRODUCT Neupopeg 6 mg solution for injection. 
IME ZDRAVILA Neupopeg 6 mg raztopina za injiciranje
Before administration, Neupopeg solution should be inspected visually for particulate matter. 
Pred uporabo morate raztopino Neupopega pregledati glede vidnih delcev.
White blood cell counts of 100 x 109/l or greater have been observed in less than 1% of patients receiving Neupopeg. 
Pri manj kot 1 % bolnikov, ki dobivajo Neupopeg, so opazili število belih krvničk, ki je enako 100 x 109/l ali višje.
Allow the pre-filled pen to reach room temperature before injecting. 
Pred injiciranjem naj se napolnjen injekcijski peresnik segreje na sobno temperaturo.
Equipment that you need To give yourself a subcutaneous injection you will need: 
Oprema, ki jo boste potrebovali
The needle cover on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions. 
Pokrovček igle pri napolnjeni injekcijski brizgi vsebuje derivat lateksa in lahko povzroča hude alergijske reakcije.
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution. 
Vsaka napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine.
The needle cover of the pre-filled pen contains dry natural rubber (a derivative of latex). 
Pokrovček igle pri napolnjenem injekcijskem peresniku vsebuje suho naravno gumo (derivat lateksa).
The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. 
Pokrovček igle pri napolnjeni injekcijski brizgi vsebuje suho naravno gumo (derivat lateksa), ki lahko povzroča alergične reakcije.
One 6 mg dose (a single pre-filled pen) of Neupopeg (SureClick) is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy. 
Za vsak cikel kemoterapije priporočajo en 6-miligramski odmerek (en napolnjen injekcijski peresnik) Neupopega (SureClick), ki je dan v obliki subkutane injekcije približno 24 ur po citotoksični kemoterapiji.
Sweet's syndrome (plum-coloured, raised, painful lesions on the limbs and sometimes the face and neck with fever) has occurred very rarely (likely to occur in fewer than 1 in 1,000 patients) but other factors may play a role. 
Redko (verjetno je, da se bo pojavil pri manj kot 1 od 1.000 bolnikov) se je pojavil Sweetov sindrom (izbočene boleče spremembe slivove barve na okončinah in včasih tudi na obrazu in vratu s povišano telesno temperaturo), tu lahko vplivajo tudi drugi dejavniki.
Pegfilgrastim 
pegfilgrastima ANC
QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 ml solution for injection. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima* v 0,6 ml raztopine za injiciranje.
Neupopeg contains the active substance pegfilgrastim. 
Zdravilo Neupopeg vsebuje zdravilno učinkovino pegfilgrastim.
Very rare (< 1/10,000) events of cutaneous vasculitis have been reported in patients treated with Neupopeg. 
Pri bolnikih, zdravljenih z Neupoegom, so zelo redko (< 1/10.000) poročali o primerih kožnega vaskulitisa.
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous use. 
IME ZDRAVILA IN POT(I) UPORABE
Rare (≥ 1/10,000 to < 1/1,000) pulmonary adverse effects, in particular interstitial pneumonia, have been reported after G-CSF administration. 
Po uporabi G-CSF so opisani redki primeri (≥ 1/10.000 do < 1/1.000) neželenih učinkov na pljučih, zlasti intersticijske pljučnice.
Do not use Neupopeg if you notice it is cloudy or there are particles in it. 
Če opazite, da je Neupopeg moten ali da v njem plavajo delci, ga ne smete uporabiti.
• Keep used syringes out of the reach and sight of children. 
• Uporabljene injekcijske brizge shranjujte nedosegljivo otrokom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING UNBLISTERED SYRINGE OUTER CARTON 
PODATKI NA ZUNANJI OVOJNINI ŠKATLICA Z INJEKCIJSKO BRIZGO V NEPRETISNI OVOJNINI
** The concentration is 20 mg/ml if the PEG moiety is included The potency of this product should not be compared to the potency of another pegylated or nonpegylated protein of the same therapeutic class. 
** Če je vključen še delež PEG, je koncentracija 20 mg/ml.
The needle cover on the pre-filled pen contains a derivative of latex and may cause severe allergic reactions. 
Pokrovček igle pri napolnjenem injekcijskem peresniku vsebuje derivat lateksa in lahko povzroča hude alergijske reakcije.
The safety and efficacy of Neupopeg have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g., nitrosoureas. 
Pri bolnikih, ki dobivajo kemoterapijo, povezano z odloženo mielosupresijo, na primer nitrozouree, varnosti in učinkovitosti Neupopega niso ovrednotili.
MARKETING AUTHORISATION NUMBER(S) EU/1/02/228/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/02/228/001
One 6 mg dose (a single pre-filled syringe) of Neupopeg is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy. 
Za vsak cikel kemoterapije priporočajo en 6-miligramski odmerek (eno napolnjeno injekcijsko brizgo) Neupopega, ki je dan v obliki subkutane injekcije približno 24 ur po citotoksični kemoterapiji.
Do not lift the prefilled pen. 
Ne dvigajte napolnjenega injekcijskega peresnika.
MARKETING AUTHORISATION NUMBER(S) EU/1/02/228/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/02/228/002
• Keep used pens out of the reach and sight of children. 
• Uporabljene injekcijske peresnike shranjujte nedosegljivo otrokom.
NAME OF THE MEDICINAL PRODUCT Neupopeg 6 mg solution for injection in a pre-filled pen. 
IME ZDRAVILA Neupopeg 6 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Neupopeg 6 mg solution for injection in a pre-filled pen pegfilgrastim 
Neupopeg 6 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku pegfilgrastim
MARKETING AUTHORISATION NUMBER(S) EU/1/02/228/003 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/02/228/003
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml (10 mg/ml) solution for injection. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
Neupopeg is essentially sodium-free. 
Neupopeg je pravzaprav brez natrija.
Disposing of used pre-filled pens 
Odlaganje rabljenih napolnjenih injekcijskih peresnikov Odlaganje rabljenih napolnjenih injekcijskih peresnikov
Rare (likely to occur in fewer than 1 in 1000 patients)cases of breathing problems have been reported after taking G-CSFs. 
Po uporabi G-CSF so opisani redki (verjetno je, da se bodo pojavili pri manj kot 1 od 1000 bolnikov) primeri težav dihanja.
NAME OF THE MEDICINAL PRODUCT Neupopeg 6 mg injection Pegfilgrastim 
Neupopeg 6 mg injekcija pegfilgrastim
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled pen contains 6 mg of pegfilgrastim in 0.6 ml (10 mg/ml) solution for injection. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsak napolnjen injekcijski peresnik vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
If there are particles in it, you must not use it. For a more comfortable injection, leave at room temperature for approximately 30 minutes. 
Da bo injiciranje manj neprijetno, pustite napolnjen injekcijski peresnik stati 30 minut zunaj hladilnika.
The abdomen can be considered when the thigh and back of arm are judged by a healthcare professional to be inappropriate. 
Če zdravstveni delavec oceni, da stegno ali zadnji del nadlakta nista primerni mesti, lahko injicirate v trebuh.
Water for injections 
OZNAKA NAPOLNJENE INJEKCIJSKE BRIZGE
PHARMACEUTICAL FORM AND CONTENTS Solution for injection in a single use pre-filled syringe (0.6 ml). 
Raztopina za injiciranje v napolnjeni injekcijski brizgi (0,6 ml) za enkratno uporabo.
NAME OF THE MEDICINAL PRODUCT Neupopeg 6 mg solution for injection Pegfilgrastim 
Neupopeg 6 mg raztopina za injiciranje pegfilgrastim